Clinical Immunoanalyzer Market: Introduction
- Clinical immunoanalyzer is a diagnostic device used to detect specific analytes in blood or in fluids by employing immunoassay processes such as chemiluminescence immunoassay, enzyme linked fluorescent immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay (RIA). An immunoanalyzer comprises washer, reagent dispenser, auto sampler, and the offered product depending upon the configuration and test options. Few clinical immunoanalyzer products use automated chemical analyzer, which reduces manual intervention and improves the workflow. These clinical immunoanalyzers are utilized in hospitals and laboratories for the detection of bacterial infections and viral toxins. These are also employed in drug monitoring, allergy testing, as cancer markers, and in detecting toxins.
Clinical Immunoanalyzer Market: Key Trends
- High prevalence and incidence rates of chronic and infectious diseases is estimated to drive the demand for clinical immunoanalyzers. Prevalence of infectious and chronic diseases across the globe drives the demand for early diagnosis. Hence, diagnosis of infectious diseases is one of the leading applications of clinical immunoanalyzers. Furthermore, investment in the development of new assays for diagnosis of various infectious diseases has been increasing. In April 2017, the U.S. Department of Health and Human Services awarded US$ 8.9 million to Siemens Healthineers for the development of Zika virus immunoassay test to be used on its Advia platform of immunoassay analyzers. High prevalence of infectious diseases is projected to propel the demand for diagnostic tests. Demand for clinical immunoanalyzers is likely to increase owing to its benefits in monitoring transfusion medicine, such as blood transfusion and organ transplant. Moreover, incidence of endocrinology diseases, such as thyroid dysfunction, diabetes mellitus, and the incidences of osteoporosis is rising owing to changing lifestyles. This is likely to boost the demand for clinical immunoanalyzers.
- The world is presently struggling with the COVID-19 pandemic. COVID-19 leads to pneumonia, severe & acute respiratory disorders, multiple organ failure, and, in severe cases, death. The geriatric population is more prone to COVID-19. The global clinical immunoanalyzer market has expanded at a rapid pace during the pandemic.
- Governments of developing countries are making significant investments to modernize healthcare infrastructure in their respective countries, which is likely to increase access to healthcare. This is expected to fuel the demand for clinical immunoanalyzer. Rise in prevalence of chronic heart diseases, especially heart attack, in developing countries presents lucrative opportunities in the global clinical immunoanalyzer market.
North America to Capture Major Share of Global Clinical Immunoanalyzer Market
- North America is projected to account for a notable share of the global clinical immunoanalyzer market during the forecast period owing to the increasing knowledge on biomarkers of various chronic diseases, which has prompted industry experts and researchers to apply this information in the development of new assays to expand the applications of automated immunoassay analyzers. Development in the fields of genomics and proteomics has expanded the database of biomarkers used by industry players to develop new assays. For instance, a chemiluminescence assay has been developed to test vitamin D deficiency, which was earlier diagnosed through manual ELISA methods. New molecular diagnostic tests are being developed for infectious diseases. Such developments in the region boost the market during the forecast period.
- The clinical immunoanalyzer market in Europe is likely to expand at a rapid pace during the forecast period, owing to an increase in research & development on clinical immunoanalyzer in the region. The clinical immunoanalyzer market in Asia Pacific is expected to expand at a high CAGR during the forecast period driven by increased prevalence and incidence rates of chronic and infectious diseases in countries, such as China and India, and rapid adoption of research technologies. The market in Middle East & Africa and Latin America is anticipated to expand during the forecast period due to an increase in incidence of chronic diseases in these regions.
Key Players Operating in Global Clinical Immunoanalyzer Market
Strategies adopted by the key players such as mergers & acquisitions, partnerships, joint ventures, and agreements are projected to boost the global clinical immunoanalyzer market. Key players hold a major share in their respective regions. Growth strategies adopted by leading players are likely to drive the global clinical immunoanalyzer market.
Major players operating in the global clinical immunoanalyzer market are listed below:
- F. Hoffmann-La Roche Ltd.
- Abbott
- Siemens Healthineers
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- bioMérieux SA
- Werfen Life
- Thermo Fisher Scientific, Inc.
- Tosoh Corporation
- Randox Laboratories
Global Clinical Immunoanalyzer Market: Research Scope
Global Clinical Immunoanalyzer Market, by Technology
- Chemiluminescence Immunoassay (CLIA)
- Enzyme Linked Fluorescent Immunoassay (ELFA)
- Enzyme Linked Immunosorbent Assay (ELISA)
- Radioimmunoassay (RIA)
- Others
Global Clinical Immunoanalyzer Market, by Application
- Cancer Markers
- Infectious Diseases
- Cardiac Disease
- Drug Monitoring
- Others
Global Clinical Immunoanalyzer Market, by End-user
- Hospitals
- Diagnostic Laboratories
- Blood Banks
- Others
Global Clinical Immunoanalyzer Market, by Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
